Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Dose Denosumab in GCTB
NCT03620149Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2019
- Primary completion
- Jul 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of denosumab in Giant Cell Tumor of Bone (GCTB), sponsored by European Organisation for Research and Treatment of Cancer. Started Sep 2019; status: terminated.
02
Drugs
denosumab
03
Conditions
Giant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on NCT03620149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620149.